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A b s t r A c t
Proton pump inhibitors are commonly used in clinical practice for the treatment of 
peptic ulcer disease and gastro-esophageal reflux and are well tolerated by the pa-
tients. Their use is rarely associated with hypersensitivity and anaphylactic reactions. 
According to the reports in the Uppsala Monitoring Center database the frequency 
of hypersensitivity reactions out of all reported adverse reactions for proton pump 
inhibitors and H2-histamine receptor antagonists were between 0.2% and 0.7%. A 
few cases of hypersensitivity to lansoprazole have been reported. Herein, we report a 
patient who developed Kounis syndrome after taking 40 mg of lansoprazole. To our 
knowledge, this is the first report of Kounis syndrome associated with lansoprazole 
administration in the world literature.
Proton pump inhibitors are the main medications currently used for the treat-
ment of various gastrointestinal disorders. In cardiac patients these agents are usu-
ally prescribed prophylactically in conjunction with aspirin administration. They are 
non-competitive inhibitors of the parietal cell membrane enzyme H+/K+ adenosine 
triphosphatase. This enzyme acts as “acid pump” or “proton pump” which constitutes 
the final stage of the hydrochloric acid secretion in the stomach. They are metabolized 
in the liver via cytochrome P450. Their use is rarely associated with side-effects and 
especially with hypersensitivity reactions. The following report concerns a patient who 
developed urticarial reaction after ingesting 30 mg of lansoprasole and immediately 
afterwards an acute inferior myocardial infarction occurred presumably related to an 
allergic reaction to the medication [1-4].
c A s E  r E P O r t
A 52 year old man was transferred to the emergency department of our hospital 
complaining of generalized itching, malaise, shortness of breath, difficulty in swallow-
ing, and abdominal pain and numbness all over his body. On examination he had an 
erythematous skin rash covering the whole body with facial edema, he was diaphoretic, 
pale, and agitated. His symptoms started 10 min after taking 30 mg of lansoprazole 
for his abdominal pain. He gave a history of previous peptic ulcer and hematemesis 
and was taking occasionally various antiulcer preparations including omeprazole and 
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ranitidine with good tolerance. He was a non-smoker without 
any previous personal or family history of allergy or other 
drug sensitivity. 
His blood pressure was 110/80 mmHg, the pulse rate 102 
beats/min regular and the electrocardiogram (ECG) was 
within normal limits (Fig. 1A). Pulse oxymetry showed an 
oxygen saturation of 2%. He was treated with 500 mg of 
hydrocortisone sodium succinate and 4 mg of dimetiridene 
intravenously. He also received inhalation of corticosteroid 
for difficulty in breathing. 
However, while he was in the emergency room, he sud-
denly developed severe retrosternal pain radiating to both 
arms and started vomiting. A second ECG (Fig. 1B) showed 
elevation of ST segment in leads II, III, aVF compatible with 
acute inferior wall myocardial infarction. His blood pressure 
dropped to 80/60 mmHg. At that time the patient was given 
a second bolus of 500 mg of hydrocortisone sodium succinate 
IV, 10 mg of morphine sulphate and a blood sample was taken 
for cardiac enzymes, troponins, histamine, tryptase, IgE im-
munoglobulins, complement protein and blood count. 
The patient was subsequently admitted to the coronary 
care unit where he was thrombolyzed with tenecteplace 
bolus of 7000 IU. His symptoms gradually subsided during 
the following 24 hours and the ECG changes returned to 
normal (Fig. 1C). Echocardiographic examination performed 
at bedside revealed hypokinesia of the inferior wall with an 
estimated ejection fraction of 50%. The results of blood test-
ing showed increased troponin T of 1.5 ng/ml (normal range 
<0.1 μg/L) and peak creatinine kinase of 1342 IU/L with 
CPK-MB of 150 IU/L. Blood eosinophils were raised to % 
but the complement proteins C3 and C4 were normal. Other 
specific blood measurements related to allergic reactions 
were increased as follows: serum tryptase 20, 35, 15 μg/l at 1, 
2, 3 hours respectively (normal range 5.6-13.5), histamine 0. 
ng/L (normal range <0.2), immunoglobulin IgE 10 IU/ml 
(normal range <110).
The patient underwent a treadmill stress test and a hy-
perventilation test which were normal. Oral test dose with 
lansoprasole was not performed in view of the acute myocar-
dial infarction as this was deemed clinically unsafe. However, 
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a hypersensitivity skin test with lansoprazole (30 mg in 1 ml 
saline) was performed, which produced a wheal of 3 mm in di-
ameter at 20 minutes. Similar testing with omeprazole (20 mg 
in 1ml saline), pantoprazole (20 mg in 1 ml saline), ranitidine 
(50 mg in ml saline) and buffered saline produced no reaction, 
thus confirming hypersensitivity limited to lansoprasole. The 
patient was discharged home on the seventh day of admis-
sion. Coronary angiography performed in the neighbouring 
University hospital showed 80% right coronary artery lesion 
and the patient underwent a successful coronary angioplasty 
and stenting procedure.
D I s c U s s I O N
To our knowledge this is the first patient in the literature 
to develop acute myocardial infarction following an allergic 
reaction after ingestion of lansoprazole. The association of 
an acute coronary syndrome and an allergic reaction has 
been suggested by Kounis (Kounis syndrome) [1]. There are 
various drugs capable to induce Kounis syndrome [5] and 
include antibiotics, analgesics, antineoplastics, contrast media, 
intravenous anesthetics, corticosteroids, non-steroidal anti-in-
flammatory drugs, thrombolytics and skin disinfectants. Few 
proton pump inhibitors used in everyday practice have been 
incriminated in rare occasions to induce hypersensitivity reac-
tions. The older preparations omeprazole [6-10], lansoprazole 
[11-14] and pantoprazole [15-17] have all been, although rarely, 
associated with hypersensitivity reactions. A recent review 
of the literature [14] has shown that only the newest proton 
pump inhibitors rabeprazol and esomeprazol are free, so far, 
of such reactions. Cross reactivity between the various brands 
has been also reported [12].
The proton pump inhibitors are modified benzimidazoles 
containing the pyridine ring and they differ from each other in 
the substitution chains. They act by increasing the intragastric 
pH levels, which may enhance the effectiveness of the local 
immune response, reduce the washout of antibiotics from the 
gastric mucosa, and lower the minimal inhibitory concentra-
tions of pH-sensitive antibacterial agents [10].
Our patient experienced an episode generalized urticaria 
after oral intake of lansoprazol which was followed by acute 
inferior myocardial infarction. The clinical presentation, the 
positive skin test to lansoprazol, the elevated IgE concentra-
tions, and the raised serum histamime and tryptase levels 
suggest that an IgE mediated mechanism was involved in 
both reactions, namely, urticaria and acute myocardial infarc-
tion. During hypersensitivity reactions vasoconstricting and 
collagen-degrating compounds are released locally and in 
peripheral circulation from activated mast cells. Preformed 
mediators such as, histamine, chymase, tryptase, neuropep-
tides, and proteoglycans, as well as newly synthesized media-
tors such as arachidonic acid products, an array of chemokines 
and cytokines, and platelet activating factor 3 are some of 
them. Clinical and experimental studies [18] have shown that 
these mediators can induce coronary artery spasm and/or 
acute myocardial infarction. In particular, histamine is raised 
in the coronary circulation of patients with variant angina and 
can induce tissue factor expression. Tryptase has been impli-
cated in acute coronary syndromes and can degrade HDL. 
Indeed, tryptase and histamine were elevated in the serum 
of the presented patient during the hypersensitivity reaction 
and the ensuing acute myocardial infarction.
This report shows that the proton pump inhibitor lan-
soprazolee can induce allergic myocardial infarction and 
should be added in the list of drugs capable to induce Kounis 
syndrome. Since cross reactivity between these agents has 
been proven, physicians should be aware of this dangerous 
association and should always think about Kounis syndrome 
when they treat hypersensitivity complications induced by any 
of these compounds.
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